<p>Unicycive Therapeutics, Inc.（纳斯达克代码：UNCY - 免费报告）- HC Wainwright 的股票研究分析师在 5 月 27 日（星期二）发布的研究报告中发布了 Unicycive Therapeutics 2026 年第四季度每股收益（EPS）预期。HC Wainwright 的分析师 S. Ramakanth 预计该公司本季度每股收益为 0.47 美元。HC Wainwright 对该股票给予了 “买入” 评级，目标价为 9.00 美元。市场普遍预计 Unicycive Therapeutics 当前全年的每股收益为（0.23）美元。</p>
<p>获取 <strong>Unicycive Therapeutics</strong> 的提醒：</p>
<p>另外，Guggenheim 在 4 月 21 日（星期一）的一份报告中开始覆盖 Unicycive Therapeutics 的股票。他们对该股票给予了 “买入” 评级，目标价为 6.00 美元。</p>
<p><strong>查看我们最新的 UNCY 股票报告</strong></p>
<h2>Unicycive Therapeutics 股票表现</h2>
<p>纳斯达克 UNCY 的股票在星期三开盘价为 0.59 美元。Unicycive Therapeutics 的 52 周低点为 0.20 美元，52 周高点为 0.96 美元。该股票的市值为 7130 万美元，市盈率为 -0.61，贝塔值为 2.14。该股票的 50 日移动平均线为 0.59 美元，200 日移动平均线为 0.61 美元。</p>
<p>Unicycive Therapeutics（纳斯达克代码：UNCY - 获取免费报告）最近于 5 月 14 日（星期三）发布了季度财报。该公司报告本季度每股收益为（0.05）美元，超出分析师普遍预期的（0.14）美元，超出幅度为 0.09 美元。</p>
<h2>Unicycive Therapeutics 的机构交易</h2>
<p>一些对冲基金最近对该股票的持仓进行了调整。Northern Trust Corp 在第四季度将其在 Unicycive Therapeutics 的股份增加了 142.4%。Northern Trust Corp 目前拥有 58,181 股该公司的股票，价值 46,000 美元，此前在上个季度增持了 34,183 股。XTX Topco Ltd 在第四季度将其在 Unicycive Therapeutics 的持股增加了 142.2%。XTX Topco Ltd 目前拥有 171,463 股该公司的股票，价值 136,000 美元，此前在上个季度增持了 100,679 股。Geode Capital Management LLC 在第四季度将其在 Unicycive Therapeutics 的持仓增加了 30.3%。Geode Capital Management LLC 目前拥有 524,487 股该公司的股票，价值 417,000 美元，此前在上个季度增持了 122,089 股。Acuta Capital Partners LLC 在第四季度将其在 Unicycive Therapeutics 的持股增加了 16.4%。Acuta Capital Partners LLC 目前拥有 2,303,000 股该公司的股票，价值 1,829,000 美元，此前在上个季度增持了 323,801 股。最后，Vivo Capital LLC 在第一季度将其在 Unicycive Therapeutics 的持仓增加了 14.0%。Vivo Capital LLC 目前拥有 11,370,152 股该公司的股票，价值 6,537,000 美元，此前在上个季度增持了 1,400,000 股。40.42% 的股票由机构投资者持有。</p>
<h2>Unicycive Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Unicycive Therapeutics, Inc. 是一家生物技术公司，专注于在美国开发治疗肾脏疾病的新疗法。该公司正在开发 Renazorb 用于治疗接受透析的慢性肾病患者的高磷血症；以及 UNI 494，目前正在进行 I 期临床试验以治疗急性肾损伤。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Unicycive Therapeutics</li>
<li>如何选择评级最高的股票</li>
<li>Wix 可能在夏季上涨 50% 的 3 个理由</li>
<li>3 只杂货股可以帮助应对通货膨胀</li>
<li>Advance Auto Parts：收益是否缓解了关税担忧？</li>
<li>Russell 2000 指数，投资者如何利用它进行盈利交易</li>
<li>3 只交易价格低于 52 周高点 50% 的被打压股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VU5DWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VU5DWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Unicycive Therapeutics 吗？</h2>
<p>在考虑 Unicycive Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Unicycive Therapeutics 并不在名单上。</p>
<p>虽然 Unicycive Therapeutics 目前在分析师中获得了强烈买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

UNCY

<p>HC Wainwright 分析师已发布 Unicycive Therapeutics (NASDAQ: UNCY) 2026 年第四季度的收益预估，预计每股收益为 $0.47。该公司维持 “买入” 评级，目标价为 $9.00。目前，全年收益的共识预估为每股 ($0.23)。Unicycive 的股票开盘价为 $0.59，52 周范围为 $0.20 至 $0.96。该公司专注于开发肾脏疾病的治疗方案，包括 Renazorb 和 UNI 494</p>

<p>Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright issued their Q4 2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a research note issued on Tuesday, May 27th. HC Wainwright analyst S. Ramakanth expects that the company will earn $0.47 per share for the quarter. HC Wainwright has a &#34;Buy&#34; rating and a $9.00 price target on the stock. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share.</p>
<div class="lb-trans"><p>Unicycive Therapeutics, Inc.（纳斯达克代码：UNCY - 免费报告）- HC Wainwright 的股票研究分析师在 5 月 27 日（星期二）发布的研究报告中发布了 Unicycive Therapeutics 2026 年第四季度每股收益（EPS）预期。HC Wainwright 的分析师 S. Ramakanth 预计该公司本季度每股收益为 0.47 美元。HC Wainwright 对该股票给予了 “买入” 评级，目标价为 9.00 美元。市场普遍预计 Unicycive Therapeutics 当前全年的每股收益为（0.23）美元。</p>
</div><p>Get <strong>Unicycive Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Unicycive Therapeutics</strong> 的提醒：</p>
</div><p>Separately, Guggenheim assumed coverage on shares of Unicycive Therapeutics in a report on Monday, April 21st. They issued a &#34;buy&#34; rating and a $6.00 price target on the stock.</p>
<div class="lb-trans"><p>另外，Guggenheim 在 4 月 21 日（星期一）的一份报告中开始覆盖 Unicycive Therapeutics 的股票。他们对该股票给予了 “买入” 评级，目标价为 6.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on UNCY</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 UNCY 股票报告</strong></p>
</div><h2>Unicycive Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Unicycive Therapeutics 股票表现</h2>
</div><p>Shares of NASDAQ UNCY opened at $0.59 on Wednesday. Unicycive Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $0.96. The stock has a market cap of $71.30 million, a PE ratio of -0.61 and a beta of 2.14. The stock has a fifty day moving average of $0.59 and a 200-day moving average of $0.61.</p>
<div class="lb-trans"><p>纳斯达克 UNCY 的股票在星期三开盘价为 0.59 美元。Unicycive Therapeutics 的 52 周低点为 0.20 美元，52 周高点为 0.96 美元。该股票的市值为 7130 万美元，市盈率为 -0.61，贝塔值为 2.14。该股票的 50 日移动平均线为 0.59 美元，200 日移动平均线为 0.61 美元。</p>
</div><p>Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.09.</p>
<div class="lb-trans"><p>Unicycive Therapeutics（纳斯达克代码：UNCY - 获取免费报告）最近于 5 月 14 日（星期三）发布了季度财报。该公司报告本季度每股收益为（0.05）美元，超出分析师普遍预期的（0.14）美元，超出幅度为 0.09 美元。</p>
</div><h2>Institutional Trading of Unicycive Therapeutics</h2>
<div class="lb-trans"><h2>Unicycive Therapeutics 的机构交易</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the stock. Northern Trust Corp increased its stake in Unicycive Therapeutics by 142.4% in the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after acquiring an additional 34,183 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Unicycive Therapeutics by 142.2% in the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock worth $136,000 after purchasing an additional 100,679 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after purchasing an additional 122,089 shares during the last quarter. Acuta Capital Partners LLC raised its holdings in shares of Unicycive Therapeutics by 16.4% during the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock valued at $1,829,000 after buying an additional 323,801 shares in the last quarter. Finally, Vivo Capital LLC lifted its position in Unicycive Therapeutics by 14.0% in the 1st quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock worth $6,537,000 after buying an additional 1,400,000 shares during the last quarter. 40.42% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金最近对该股票的持仓进行了调整。Northern Trust Corp 在第四季度将其在 Unicycive Therapeutics 的股份增加了 142.4%。Northern Trust Corp 目前拥有 58,181 股该公司的股票，价值 46,000 美元，此前在上个季度增持了 34,183 股。XTX Topco Ltd 在第四季度将其在 Unicycive Therapeutics 的持股增加了 142.2%。XTX Topco Ltd 目前拥有 171,463 股该公司的股票，价值 136,000 美元，此前在上个季度增持了 100,679 股。Geode Capital Management LLC 在第四季度将其在 Unicycive Therapeutics 的持仓增加了 30.3%。Geode Capital Management LLC 目前拥有 524,487 股该公司的股票，价值 417,000 美元，此前在上个季度增持了 122,089 股。Acuta Capital Partners LLC 在第四季度将其在 Unicycive Therapeutics 的持股增加了 16.4%。Acuta Capital Partners LLC 目前拥有 2,303,000 股该公司的股票，价值 1,829,000 美元，此前在上个季度增持了 323,801 股。最后，Vivo Capital LLC 在第一季度将其在 Unicycive Therapeutics 的持仓增加了 14.0%。Vivo Capital LLC 目前拥有 11,370,152 股该公司的股票，价值 6,537,000 美元，此前在上个季度增持了 1,400,000 股。40.42% 的股票由机构投资者持有。</p>
</div><h2>Unicycive Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Unicycive Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.</p>
<div class="lb-trans"><p>Unicycive Therapeutics, Inc. 是一家生物技术公司，专注于在美国开发治疗肾脏疾病的新疗法。该公司正在开发 Renazorb 用于治疗接受透析的慢性肾病患者的高磷血症；以及 UNI 494，目前正在进行 I 期临床试验以治疗急性肾损伤。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Unicycive Therapeutics</li>
<li>How to Choose Top Rated Stocks</li>
<li>3 Reasons Wix Could Rally 50% Into the Summer</li>
<li>3 Grocery Stocks That Can Help Take a Bite Out of Inflation</li>
<li>Advance Auto Parts: Did Earnings Defuse Tariff Concerns?</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Unicycive Therapeutics</li>
<li>如何选择评级最高的股票</li>
<li>Wix 可能在夏季上涨 50% 的 3 个理由</li>
<li>3 只杂货股可以帮助应对通货膨胀</li>
<li>Advance Auto Parts：收益是否缓解了关税担忧？</li>
<li>Russell 2000 指数，投资者如何利用它进行盈利交易</li>
<li>3 只交易价格低于 52 周高点 50% 的被打压股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VU5DWQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=UNCY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Unicycive Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Unicycive Therapeutics 吗？</h2>
</div><p>Before you consider Unicycive Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Unicycive Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Unicycive Therapeutics 并不在名单上。</p>
</div><p>While Unicycive Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Unicycive Therapeutics 目前在分析师中获得了强烈买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 发布了对 Unicycive Therapeutics 第四季度收益的预估